-
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast CancerDaiichi Sankyo2026-09-18 14:03:16Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease
-
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2026-09-01 08:40:58Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line
-
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular riskDaiichi Sankyo2026-08-27 17:30:24New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia
-
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization OrganizationDaiichi Sankyo2026-08-27 17:31:47Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
-
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for ImmunotherapyDaiichi Sankyo2026-07-31 08:40:18Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line
-
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2026-07-24 12:32:03Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with
-
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid TumorsDaiichi Sankyo2026-06-30 16:06:21Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for
-
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for ImmunotherapyDaiichi Sankyo2026-06-30 16:03:43Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic
-
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026Daiichi Sankyo2026-06-09 16:24:17Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS
-
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid TumorsDaiichi Sankyo2026-06-09 12:59:47Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive
